To determine the association between the focal atrophy measures on antemortem MRI and postmortem neuropathologic classification of dementia with Lewy bodies (DLB) using the Third Report of the DLB Consortium criteria.
Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia after Alzheimer disease (AD); however, many patients with DLB also have AD pathology. [1] [2] [3] [4] [5] Imaging markers that predict the contribution of AD to the dementia syndrome in DLB would have an important role in treatment decisions and assessing responsiveness to treatments targeting disease-specific pathologies.
According to the Third Report of the DLB Consortium criteria, 6 the pathologic diagnosis of DLB is made by considering both AD and Lewy body (LB) pathologies. For example, patients with limbic LBs are diagnosed as high likelihood DLB if they have low likelihood AD, but diagnosed as low likelihood DLB if they have high likelihood AD. Therefore, in vivo identification of AD and LB pathology is critical for the differential diagnosis of DLB.
Hippocampal atrophy on MRI is associated with the neurofibrillary tangle (NFT) pathology in AD. [7] [8] [9] [10] [11] [12] Typically, DLB is characterized by normal hippocampal volumes on MRI and preserved hippocampal neurons at autopsy. [13] [14] [15] DLB has also been associated with reduced dorsal mesopontine gray matter (GM) 16, 17 and amygdalar 16, 18 volume. However, these findings have been limited to patients with a clinical or pathologic diagnosis of DLB and did not include patients with mixed AD and LBϪrelated pathology. In the community, AD commonly coexists with LB pathology, 1 which forms the conceptual framework of the current diagnostic criteria for DLB. 6 Our objective was to determine whether MRI measures of focal atrophy are associated with the neuropathologic classification of DLB.
METHODS Subjects. Patients were recruited from the Mayo Clinic Alzheimer Disease Research Center, a dementia clinicϪbased cohort, and the Alzheimer Disease Patient Registry (ADPR), a community clinicϪbased cohort. We retrospectively identified consecutive patients who had an antemortem MRI and autopsy during years 1994Ϫ2009 with neuropathologic diagnoses ranging from low to high likelihood DLB according to the Third Report of the DLB Consortium criteria (n ϭ 56). 6 We also included subjects without LB pathology, who met the criteria for low likelihood AD (n ϭ 27) and did not have dementia at the time of their MRI. We refer to these individuals as control subjects. Another comparison group included patients with dementia with no LBs but high likelihood AD (n ϭ 33) based on National Institute on AgingϪReagan criteria. 19 Individuals participating in the Alzheimer Disease Research Center/Alzheimer Disease Patient Registry studies undergo annual clinical and neuropsychological examinations, brain MRI, and routine laboratory tests. The Global Deterioration Scale is routinely used as a noncognitive rating for dementia severity. 20 Clinical criteria were not used for inclusion and exclusion of subjects in this study. Inclusion and exclusion were solely based on the neuropathologic findings. For inclusion in this study, subjects had autopsies that showed either AD or LB pathology or neither and underwent antemortem MRI examinations. Subjects were excluded if they had other primary neurologic disease at the time of the MRI examination. Specifically, individuals with cortical infarctions, neoplasm, subdural hematoma, hydrocephalus, or other neurologic illnesses that typically interfere with cogni-tive function were excluded. The exception was the inclusion of subjects with leukoaraiosis and lacunar infarctions.
Diagnosis at the time of the MRI was made according to the established clinical criteria during a consensus conference involving neurologists, neuropsychologists, and nurses who evaluated the patients. Diagnosis of probable DLB was made according to the Third Report of the DLB Consortium criteria for DLB, 6 which was recently validated with an autopsy sample. 21 Diagnosis of probable AD was made according to the National Institute of Neurological and Communicative Disorders and Stroke/ Alzheimer's Disease and Related Disorder's Association criteria for AD. 22 Diagnosis of mild cognitive impairment (MCI) was made according to the criteria of Petersen. 23 Standard protocol approvals, registrations, and patient consents. This study was approved by the Mayo Clinic Institutional Review Board, and informed consent for participation was obtained from every subject or an appropriate surrogate.
Neuropathologic assessment. Standardized methods were used for the neuropathologic assessment by 2 expert neuropathologists (D.W.D. and J.E.P.). Sampling was done according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) protocol 24 and the Third Report of the DLB Consortium. 6 NFTs and corresponding Braak stage 25 were detected using thioflavin-S microscopy or Bielschowsky silver stain, and classified according to National Institutes of AgingϪReagan criteria, which use the CERAD method for assessing neuritic plaques. 19 Regional involvement with LBs classified as brainstem, limbic, and neocortical was determined based on LB counts using a polyclonal antibody to ␣-synuclein. The neuropathologic diagnosis of DLB was made according to the Third Report of the DLB Consortium criteria without consideration of clinical presentation. 6 MRI acquisition and analysis. MRI scans were performed at 1.5 T (GE Healthcare). A 3-dimensional high-resolution spoiled gradient recalled acquisition with repetition time/echo time/inversion time ϭ 7/3/900 msec, flip angle 8°, in-plane resolution of 1.0 mm, and slice thickness of 1.2 mm was performed for the automated segmentation of regional volumes. We used the fully automated FreeSurfer 4.5 (http://surfer.nmr.mgh. harvard.edu) algorithm to analyze the hippocampal and amygdalar volumes. The volumes of the amygdalae and the hippocampi were computed by averaging the right and left volumes. Dorsal mesopontine GM volume was determined by an automated region of interest (ROI) analysis. Dorsal mesopontine GM ROI Table 1 Pathologic classification of the study sample
Low likelihood AD Intermediate likelihood AD High likelihood AD

Brainstem LBs
Low likelihood DLB (n ϭ 0) Low likelihood DLB (n ϭ 0) Low likelihood DLB (n ϭ 0)
Limbic (transitional)
High likelihood DLB (n ϭ 5) Intermediate likelihood DLB (n ϭ 2) Low likelihood DLB (n ϭ 9) showing the maximum GM loss in patients with probable DLB was determined on a custom template in a previous study. 17 Each subject's high resolution T1-weighted MRI scan in the current study was spatially normalized to the custom template and segmented into GM, white matter, and CSF using the unified segmentation model of SPM5, giving a discrete cosine transformation. Then for each subject, inverse of this transformation was applied to warp the dorsal mesopontine GM ROIs to the subject's native anatomic space to determine the GM volume in the segmented T1-weighted MRIs. All ROIs were visually inspected for the quality control of volumetric analysis of the hippocampus, amygdala, and dorsal mesopontine GM.
Diffuse (neocortical)
Statistical analysis. We analyzed regional volumes after scaling them by the subject's total intracranial volume. To evaluate groupwise differences, we used analysis of covariance (ANCOVA) with pathologic diagnosis treated as the main effect and age, sex, and the natural log of years from MRI to death treated as covariates. We performed a trend test among DLB groups only by coding the groups as 1 for low likelihood DLB, 2 for intermediate likelihood DLB, and 3 for high likelihood DLB. This approach is essentially equivalent to testing an unbalanced analysis of varianceϪbased contrast with the contrast coefficients of Ϫ1, 0, and ϩ1 weighted by sample size. 26 Because of right skewness, we analyzed the square root of dorsal mesopontine GM volumes in our models. We evaluated the effect of Braak NFT stage on total intracranial volumeϪscaled ROI volume among those with DLB only using linear regression and the same adjustment variables as in the ANCOVA models. To summarize the association with Braak NFT stage, we report Pearson partial correlations, denote by r p , taking into account the effect of age, sex, and the natural log of years from MRI to death. We assessed how well regional volumes could discriminate between pathologically defined AD vs high likelihood DLB by reporting the area under the receiver operating characteristic curve (AUROC) from logistic regression models among these 2 groups of subjects. As in our ANCOVA models, the logistic models were adjusted for age, sex, and the natural log of years from MRI to death. We did not adjust for multiple comparisons. 27 Graphical summaries of the data revealed some subjects to have outlying volumes. As part of the model-fitting process we examined the regression model diagnostics and found that the regression assumptions were wellsatisfied and that these outlying points were not overly influential. All analyses were performed with R statistical software version 2.13.2 (http://www.R-project.org). Hippocampal volumes were different among the diagnostic groups on ANCOVA ( p Ͻ 0.001) (figure 1). Patients with high likelihood DLB had normal hippocampal volumes compared with those of con- Volumes of the amygdalae also differed among the diagnostic groups on ANCOVA ( p Ͻ 0.001) ( figure 2) . Unlike for the hippocampal volumes, the high likelihood DLB group showed a trend for smaller amygdalar volume than control subjects ( p ϭ 0.07), and no difference was observed among the amygdalar volumes of low and high likelihood DLB groups ( p ϭ 0.17). Amygdalar volumes were larger in the high likelihood DLB group compared to the AD ( p ϭ 0.002) and intermediate likelihood DLB
RESULTS
( p Ͻ 0.001) groups. The amygdalar volumes in intermediate ( p Ͻ 0.001) and low ( p ϭ 0.002) likelihood DLB groups were smaller than those for normal control subjects, but similar to those for the AD group ( p Ͼ 0.09). Also similar to the hippocampal findings, there was a trend of increased amygdalar volumes from low to intermediate to high likelihood DLB ( p ϭ 0.02; trend test), and there was a significant relationship between amygdalar volumes and Braak NFT stage (r p ϭ Ϫ0.49; p Ͻ 0.001).
Patients with high likelihood DLB had significantly smaller dorsal mesopontine GM volumes compared with those of normal control subjects ( p ϭ 0.004) and patients with AD ( p ϭ 0.01) ( figure 3 ). There was no difference in dorsal mesopontine GM volume when the patients with intermediate and low likelihood DLB were compared with normal control subjects or patients with AD ( p Ն 0.40). Patients with intermediate and low likelihood DLB had similar dorsal mesopontine GM volumes ( p ϭ 0.64), which were larger than the dorsal mesopontine GM volumes of patients with high likelihood DLB ( p ϭ 0.03). Dorsal mesopontine GM volume increased from low to intermediate to high likelihood DLB ( p ϭ 0.01; trend test). Smaller dorsal mesopontine GM volumes were associated with a lower Braak NFT stage (r p ϭ 0.28; p ϭ 0.04) in patients with LB-related pathology.
The AUROC for differentiating high likelihood AD and high likelihood DLB with hippocampal volumes was 0.87, with amygdalar volumes was 0.76, and with dorsal mesopontine volumes was 0.74. When both hippocampal and dorsal mesopontine GM volumes were included in the model for differentiating high likelihood AD and high likelihood DLB, the AUROC improved to 0.92. The AUROC was at 0.87 when both hippocampal and amygdalar volumes were included and was 0.85 when both amygdalar and dorsal mesopontine GM volumes were included in the model. Hippocampal ( p ϭ 0.54), amygdalar ( p ϭ 0.13), and dorsal mesopontine GM ( p ϭ 0.17) volumes were not different among the limbic and neocortical LB pathology groups.
DISCUSSION
In the current study, pathologic classification of DLB was made according to the likelihood classification proposed by the Third Report of the DLB Consortium criteria. 6 Using this classification scheme, antemortem MRI hippocampal volumes in patients with high likelihood DLB were indistinguishable from those of control subjects (i.e., individuals with low likelihood AD and no LBrelated pathology), whereas low and intermediate likelihood DLB groups showed significantly smaller hippocampal volumes during life. Moreover, within the DLB pathologic groups, there was a significant stepwise relationship with greater hippocampal volume from low to intermediate to high likelihood DLB. These findings are in agreement with the reports on preservation of hippocampal volumes in patients with clinically diagnosed and pathologically confirmed DLB. 15, 17, 28 The current data also show a relationship between hippocampal volume and Braak NFT stage in patients with DLB, suggesting that hippocampal volume is probably related to the existing NFT pathology and not to the LB pathology. These data provide further evidence that hippocampal atrophy on MRI is a sensitive marker for ADrelated pathology, specifically for NFT-associated neurodegeneration. [7] [8] [9] [10] [11] [12] 29 An exception to this association is hippocampal-sparing atypical AD. 30, 31 None of the patients in the current DLB cohort had the pathologic features of atypical hippocampal-sparing AD. We note that hippocampal atrophy is also a feature of hippocampal sclerosis and frontotemporal lo-bar degeneration, which seldom accompany LBrelated pathology in older adults. 9, 32 There was a trend for smaller amygdalar volumes in patients with high likelihood DLB than in normal control subjects, whereas amygdalar volumes in low and intermediate likelihood DLB groups more closely resembled those of the AD group. Higher Braak NFT stage was associated with smaller amygdalar volume, but this association with the Braak NFT stage was relatively weaker than the association between Braak NFT stage and hippocampal volume in patients with LB pathology. Although amygdala is a medial temporal limbic structure that is involved with the NFT pathology of AD early in the disease course, the finding of a weaker association with NFT pathology in the amygdala compared with the hippocampus may occur because the amygdala is also highly vulnerable to LB-related pathology. 33 An increase in amygdalar diffusivity has been observed on diffusion tensor imaging in DLB, 34 and volume of the amygdala on MRI was associated with LB pathology. 16, 18 In agreement with these previous reports, we found a trend of smaller amygdalar volumes in patients with a high likelihood of DLB compared with the control subjects; however, this finding did not reach statistical significance. Taken together with the findings of previous studies, both AD and DLB pathologies appear to synergistically influence amygdalar volume in patients with DLB.
Dorsal mesopontine GM atrophy distinguished patients with high likelihood DLB from to control subjects and those with AD. We previously showed that dorsal mesopontine GM atrophy distinguished patients with clinically diagnosed DLB and AD. 17 In the current study, we confirm this finding in patients with high likelihood DLB. Furthermore, dorsal mesopontine GM volume decreased from low to high likelihood DLB and was positively correlated with Braak NFT stage (i.e., greater atrophy with smaller Braak NFT stage). This finding suggests that the dorsal mesopontine GM atrophy is probably not related to the underlying AD pathology.
Early LB-related pathology involves the midbrain, pontine, and basal forebrain nuclei of primarily the cholinergic and dopaminergic systems. 33 Besides the dopaminergic neurons of substantia nigra, the cholinergic neurons in the dorsal mesopontine nuclei, specifically the pedunculopontine tegmental and lateral dorsal tegmental nuclei, are involved with the LB-related pathology with significant loss of cholinergic neurons. 33, 35 Degeneration in the dorsal mesopontine region may involve other neurotransmitter systems including the noradrenergic system because of degeneration in the locus coeruleus and the serotonergic system via damage to the dorsal raphe nu- clei. 36, 37 The mesopontine nuclei are also affected in AD, [37] [38] [39] although there is some evidence that they are more affected in DLB than in AD. 39 Our finding of a smaller dorsal mesopontine GM volume in patients with DLB than in those with AD agrees with this observation. The distribution of LB pathology, whether it was limbic or neocortical, was not related to hippocampal, amygdalar, or dorsal mesopontine GM volumes. Put differently, whether the LB pathology extends into the neocortex or remains confined to brainstem and limbic regions does not affect antemortem MRI volumes of these brain regions. This is possibly because mesopontine nuclei are significantly involved with the LB-related neurodegeneration both in the limbic and neocortical LB stages. Although it is possible that atrophy is less severe in brainstem-only LBs compared with limbic and neocortical LBs, we could not test this difference because our cohort did not include patients with brainstem-only LBs. Further examination of brainstem-only LBs may be helpful to better understand the association between volume loss in the mesopontine nuclei and LB pathology.
A limitation of this study is that our cohort was confined to the spectrum of DLB and AD pathologies and did not include other diagnostic entities such as cerebrovascular disease and other conditions known to affect hippocampal volume, such as hippocampal sclerosis and frontotemporal lobar degeneration. 9, 32 We excluded other diagnostic entities because our objective was to identify focal atrophic changes on MRI associated with the pathologic classification of DLB. Further investigation is needed to determine the sensitivity and specificity of these magnetic resonance volumetric measurements in predicting the underlying pathology in a wider sampling of conditions. Moreover, larger cohort studies are needed to assess the diagnostic utility of these measurements in individual subjects and clinical settings.
These data demonstrate the focal atrophic changes on antemortem MRI in patients with mixed DLB and AD pathology classified according to the Third Report of the DLB Consortium criteria. In patients with DLB, hippocampal atrophy is a strong predictor of NFT pathology of AD, and dorsal mesopontine GM atrophy is associated with DLB. Amygdalar atrophy may be associated with both AD and DLB and does not appear to improve diagnostic discrimination of high likelihood AD and DLB when considered with hippocampal volumes. Because a majority of patients with DLB in the community have overlapping AD and DLB pathologies, dorsal mesopontine GM and hippocampal atrophy on MRI may be complementary in determining the contribution of DLB and AD pathologies to the dementia syndrome and prediction of pathologic classification in life. Determining the presence and severity of DLB and AD pathologies through noninvasive imaging markers would be critical for making decisions on disease-specific treatments in patients with DLB.
AUTHOR CONTRIBUTIONS
K. Kantarci: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, acquisition of data, study supervision, obtaining funding. T. Ferman: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data, obtaining funding. B. Boeve: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data, study supervision. S. Weigand: drafting/revising the manuscript, analysis or interpretation of data, statistical analysis. S. Przybelski: analysis or interpretation of data, statistical analysis. P. Vemuri: analysis or interpretation of data, contribution of vital reagents/tools/patients. M. Murray: drafting/revising the manuscript. M. Senjem: drafting/revising the manuscript, analysis or interpretation of data, contribution of vital reagents/tools/patients. G. Smith: drafting/revising the manuscript, acquisition of data, obtaining funding. D. Knopman: drafting/revising the manuscript, acquisition of data. R. Petersen: drafting/revising the manuscript, obtaining funding. C. Jack: drafting/revising the manuscript, analysis or interpretation of data, study supervision. J. Parisi: analysis or 
